A phase I trial on metastatic melanoma patients (n = 24) with tremelimumab (anti-PD-1) and CP-893,870 (a CD40-agonist mAb) led to 27% ORR, 26-month OS and complete response in 8% of cases. The gene discussed is RPL17; the disease is metastatic melanoma.